Entero Therapeutics Gross Profit

The latest gross profit for ENTO is $0 as of March 2026. That compares with $-36K in the prior-year period — up 100.0% year over year. That is below the sector sector average of $600M. Investors often review this figure alongside Entero Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, ENTO's gross profit moved from $-36K to $0 — a 100.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Entero Therapeutics's operating scale or balance-sheet position.

Against its sector companies, ENTO currently prints $0 for gross profit, while the sector average sits near $600M. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Entero Therapeutics's growth, margins, and balance sheet.

A gross profit figure of $0 for ENTO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $600M. Explore the charts below for those layers of context.

After noting ENTO's gross profit ($0), review year-over-year change from $-36K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.